A review on newly approved PARP inhibitors: Talazoparib and Olaparib
This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.
Hlavní autor: | Karim, Azrin |
---|---|
Další autoři: | Islam, Farzana |
Médium: | Project report |
Jazyk: | English |
Vydáno: |
Brac University
2024
|
Témata: | |
On-line přístup: | http://hdl.handle.net/10361/24372 |
Podobné jednotky
-
A review on potential of PARP inhibitors in the treatment of prostate cancer
Autor: Islam, Saidul
Vydáno: (2022) -
Association of XRCC1 and XPD polymorphism with risk of prostate cancer in Bangladesh population
Autor: Ahmed, Nafisa
Vydáno: (2023) -
SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy
Autor: Meem, Manila
Vydáno: (2023) -
Mutation in DNA polymerase γ: mitochondrial disorders
Autor: Hossain, Sadman Sanjid
Vydáno: (2023) -
RIPK pathway, as a potential target, for cancer treatment - a review
Autor: Jahan, Nusrat
Vydáno: (2024)